News / Taiwan / economic_daily
Biotech Stocks Lead Emerging Board Gains as Medeor Therapeutics Surges Over 40%
Health Technology · Biotechnology · economic_daily · 2026-09-11
7729
Despite broader market volatility, biotech stocks dominated the Emerging Board this week, with Medeor Therapeutics leading the pack on stem cell research.
What Happened
Market Overview: The Emerging Board experienced high-level volatility this week, with the number of declining stocks outpacing gainers, resulting in an average gain of 0.3%. Despite the broader market's weakness, the biotechnology and medical sector demonstrated significant resilience, attracting substantial investor interest.
Sector Leaders: Biotech and medical stocks accounted for seven of the top ten gainers on the Emerging Board, underscoring strong market enthusiasm for drug development and medical technology. Medeor Therapeutics stood out with a weekly gain of over 40%, driven by its stem cell drug research.
Top Performers: In addition to Medeor Therapeutics, other biotech companies such as Taiho, Guang Sheng Biotech, iXensor, and Weis also ranked among the top gainers. Electronic stocks, including Yulian, Qiding Technology, and Chip-Tech, also maintained steady performance to secure spots in the top ten.
Investor Sentiment: Sentiment remains positive toward the long-term prospects of the biotech industry, particularly for companies with clear R&D milestones. While the Emerging Board remains inherently volatile, the strong performance of specific biotech stocks indicates that investors are actively seeking out niche opportunities with high growth potential.